<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:46:57Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:3535370" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:3535370</identifier><datestamp>2013-01-04</datestamp><setSpec>springeropen</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Hum Genet</journal-id>
      <journal-id journal-id-type="iso-abbrev">Hum. Genet</journal-id>
      <journal-title-group>
        <journal-title>Human Genetics</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0340-6717</issn>
      <issn pub-type="epub">1432-1203</issn>
      <publisher>
        <publisher-name>Springer-Verlag</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC3535370</article-id>
      <article-id pub-id-type="pmcid">PMC3535370</article-id>
      <article-id pub-id-type="pmc-uid">3535370</article-id>
      <article-id pub-id-type="pmid">23064873</article-id>
      <article-id pub-id-type="publisher-id">1229</article-id>
      <article-id pub-id-type="doi">10.1007/s00439-012-1229-4</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Investigation</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title><italic>HOXB13</italic> is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG)</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Xu</surname>
            <given-names>Jianfeng</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lange</surname>
            <given-names>Ethan M.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3"/>
          <xref ref-type="aff" rid="Aff4"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lu</surname>
            <given-names>Lingyi</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zheng</surname>
            <given-names>Siqun L.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Zhong</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Thibodeau</surname>
            <given-names>Stephen N.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5"/>
          <xref ref-type="aff" rid="Aff6"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cannon-Albright</surname>
            <given-names>Lisa A.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff7"/>
          <xref ref-type="aff" rid="Aff8"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Teerlink</surname>
            <given-names>Craig C.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff7"/>
          <xref ref-type="aff" rid="Aff8"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Camp</surname>
            <given-names>Nicola J.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff7"/>
          <xref ref-type="aff" rid="Aff8"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Johnson</surname>
            <given-names>Anna M.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3"/>
          <xref ref-type="aff" rid="Aff9"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zuhlke</surname>
            <given-names>Kimberly A.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3"/>
          <xref ref-type="aff" rid="Aff9"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Stanford</surname>
            <given-names>Janet L.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff10"/>
          <xref ref-type="aff" rid="Aff11"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ostrander</surname>
            <given-names>Elaine A.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff10"/>
          <xref ref-type="aff" rid="Aff12"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wiley</surname>
            <given-names>Kathleen E.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff13"/>
          <xref ref-type="aff" rid="Aff14"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Isaacs</surname>
            <given-names>Sarah D.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff13"/>
          <xref ref-type="aff" rid="Aff14"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Walsh</surname>
            <given-names>Patrick C.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff13"/>
          <xref ref-type="aff" rid="Aff14"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Maier</surname>
            <given-names>Christiane</given-names>
          </name>
          <xref ref-type="aff" rid="Aff15"/>
          <xref ref-type="aff" rid="Aff16"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Luedeke</surname>
            <given-names>Manuel</given-names>
          </name>
          <xref ref-type="aff" rid="Aff15"/>
          <xref ref-type="aff" rid="Aff16"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Vogel</surname>
            <given-names>Walther</given-names>
          </name>
          <xref ref-type="aff" rid="Aff15"/>
          <xref ref-type="aff" rid="Aff17"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schleutker</surname>
            <given-names>Johanna</given-names>
          </name>
          <xref ref-type="aff" rid="Aff18"/>
          <xref ref-type="aff" rid="Aff19"/>
          <xref ref-type="aff" rid="Aff20"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wahlfors</surname>
            <given-names>Tiina</given-names>
          </name>
          <xref ref-type="aff" rid="Aff18"/>
          <xref ref-type="aff" rid="Aff19"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tammela</surname>
            <given-names>Teuvo</given-names>
          </name>
          <xref ref-type="aff" rid="Aff18"/>
          <xref ref-type="aff" rid="Aff21"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schaid</surname>
            <given-names>Daniel</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5"/>
          <xref ref-type="aff" rid="Aff22"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>McDonnell</surname>
            <given-names>Shannon K.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5"/>
          <xref ref-type="aff" rid="Aff22"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>DeRycke</surname>
            <given-names>Melissa S.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5"/>
          <xref ref-type="aff" rid="Aff6"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cancel-Tassin</surname>
            <given-names>Geraldine</given-names>
          </name>
          <xref ref-type="aff" rid="Aff23"/>
          <xref ref-type="aff" rid="Aff24"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cussenot</surname>
            <given-names>Olivier</given-names>
          </name>
          <xref ref-type="aff" rid="Aff23"/>
          <xref ref-type="aff" rid="Aff50"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wiklund</surname>
            <given-names>Fredrik</given-names>
          </name>
          <xref ref-type="aff" rid="Aff25"/>
          <xref ref-type="aff" rid="Aff26"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>GrÃ¶nberg</surname>
            <given-names>Henrik</given-names>
          </name>
          <xref ref-type="aff" rid="Aff25"/>
          <xref ref-type="aff" rid="Aff26"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Eeles</surname>
            <given-names>Ros</given-names>
          </name>
          <xref ref-type="aff" rid="Aff27"/>
          <xref ref-type="aff" rid="Aff28"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Easton</surname>
            <given-names>Doug</given-names>
          </name>
          <xref ref-type="aff" rid="Aff27"/>
          <xref ref-type="aff" rid="Aff29"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kote-Jarai</surname>
            <given-names>Zsofia</given-names>
          </name>
          <xref ref-type="aff" rid="Aff27"/>
          <xref ref-type="aff" rid="Aff28"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Whittemore</surname>
            <given-names>Alice S.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff30"/>
          <xref ref-type="aff" rid="Aff31"/>
          <xref ref-type="aff" rid="Aff32"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hsieh</surname>
            <given-names>Chih-Lin</given-names>
          </name>
          <xref ref-type="aff" rid="Aff30"/>
          <xref ref-type="aff" rid="Aff33"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Giles</surname>
            <given-names>Graham G.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff27"/>
          <xref ref-type="aff" rid="Aff34"/>
          <xref ref-type="aff" rid="Aff35"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hopper</surname>
            <given-names>John L.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff27"/>
          <xref ref-type="aff" rid="Aff34"/>
          <xref ref-type="aff" rid="Aff35"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Severi</surname>
            <given-names>Gianluca</given-names>
          </name>
          <xref ref-type="aff" rid="Aff27"/>
          <xref ref-type="aff" rid="Aff34"/>
          <xref ref-type="aff" rid="Aff35"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Catalona</surname>
            <given-names>William J.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff36"/>
          <xref ref-type="aff" rid="Aff37"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mandal</surname>
            <given-names>Diptasri</given-names>
          </name>
          <xref ref-type="aff" rid="Aff38"/>
          <xref ref-type="aff" rid="Aff39"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ledet</surname>
            <given-names>Elisa</given-names>
          </name>
          <xref ref-type="aff" rid="Aff38"/>
          <xref ref-type="aff" rid="Aff39"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Foulkes</surname>
            <given-names>William D.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff27"/>
          <xref ref-type="aff" rid="Aff40"/>
          <xref ref-type="aff" rid="Aff51"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hamel</surname>
            <given-names>Nancy</given-names>
          </name>
          <xref ref-type="aff" rid="Aff27"/>
          <xref ref-type="aff" rid="Aff40"/>
          <xref ref-type="aff" rid="Aff51"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mahle</surname>
            <given-names>Lovise</given-names>
          </name>
          <xref ref-type="aff" rid="Aff27"/>
          <xref ref-type="aff" rid="Aff41"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Moller</surname>
            <given-names>Pal</given-names>
          </name>
          <xref ref-type="aff" rid="Aff27"/>
          <xref ref-type="aff" rid="Aff41"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Powell</surname>
            <given-names>Isaac</given-names>
          </name>
          <xref ref-type="aff" rid="Aff42"/>
          <xref ref-type="aff" rid="Aff43"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bailey-Wilson</surname>
            <given-names>Joan E.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff42"/>
          <xref ref-type="aff" rid="Aff44"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Carpten</surname>
            <given-names>John D.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff42"/>
          <xref ref-type="aff" rid="Aff45"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Seminara</surname>
            <given-names>Daniela</given-names>
          </name>
          <xref ref-type="aff" rid="Aff46"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cooney</surname>
            <given-names>Kathleen A.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3"/>
          <xref ref-type="aff" rid="Aff9"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Isaacs</surname>
            <given-names>William B.</given-names>
          </name>
          <address>
            <email>wisaacs@jhmi.edu</email>
          </address>
          <xref ref-type="aff" rid="Aff13"/>
          <xref ref-type="aff" rid="Aff14"/>
        </contrib>
        <contrib contrib-type="author">
          <collab>International Consortium for Prostate Cancer Genetics</collab>
        </contrib>
        <aff id="Aff1"><label/>Data Coordinating Center for the ICPCG, Wake Forest University School of Medicine, Winston-Salem, NC USA </aff>
        <aff id="Aff2"><label/>Center for Cancer Genomics, Wake Forest University School of Medicine, Winston-Salem, NC USA </aff>
        <aff id="Aff3"><label/>University of Michigan ICPCG Group, University of Michigan Medical School, Ann Arbor, MI USA </aff>
        <aff id="Aff4"><label/>Departments of Genetics and Biostatistics, University of North Carolina, Chapel Hill, NC USA </aff>
        <aff id="Aff5"><label/>Mayo Clinic ICPGC Group, Mayo Clinic, Rochester, MN USA </aff>
        <aff id="Aff6"><label/>Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN USA </aff>
        <aff id="Aff7"><label/>University of Utah ICPCG Group, University of Utah School of Medicine, Salt Lake City, UT USA </aff>
        <aff id="Aff8"><label/>Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT USA </aff>
        <aff id="Aff9"><label/>Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI USA </aff>
        <aff id="Aff10"><label/>Fred Hutchinson Cancer Research Center (FHCRC) ICPCG Group, Seattle, WA USA </aff>
        <aff id="Aff11"><label/>Division of Public Health Sciences, FHCRC, Seattle, WA USA </aff>
        <aff id="Aff12"><label/>Cancer Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, MD USA </aff>
        <aff id="Aff13"><label/>Johns Hopkins University ICPCG Group, Baltimore, MD USA </aff>
        <aff id="Aff14"><label/>Department of Urology, Johns Hopkins Medical Institutions, Johns Hopkins Hospital, Marburg 115, 600 North Wolfe Street, Baltimore, MD 21287 USA </aff>
        <aff id="Aff15"><label/>University of Ulm ICPCG Group, University of Ulm, Ulm, Germany </aff>
        <aff id="Aff16"><label/>Department of Urology, University of Ulm, Ulm, Germany </aff>
        <aff id="Aff17"><label/>Institute of Human Genetics, University of Ulm, Ulm, Germany </aff>
        <aff id="Aff18"><label/>University of Tampere ICPCG Group, University of Tampere and Fimlab Laboratories, Tampere, Finland </aff>
        <aff id="Aff19"><label/>Institute of Biomedical Technology/BioMediTech, University of Tampere and Fimlab Laboratories, Tampere, Finland </aff>
        <aff id="Aff20"><label/>Department of Medical Biochemistry and Genetics, University of Turku, Turku, Finland </aff>
        <aff id="Aff21"><label/>Department of Urology, Tampere University Hospital, Tampere, Finland </aff>
        <aff id="Aff22"><label/>Department of Health Sciences Research, Mayo Clinic, Rochester, MN USA </aff>
        <aff id="Aff23"><label/>CeRePP ICPCG Group, Paris, France </aff>
        <aff id="Aff50"><label/>Department of Urology, APHP, Hospital Tenon, Paris, France </aff>
        <aff id="Aff24"><label/>CeRePP UPMC University, Paris, France </aff>
        <aff id="Aff25"><label/>Karolinska ICPCG Group, Karolinska Institutet, Stockholm, Sweden </aff>
        <aff id="Aff26"><label/>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden </aff>
        <aff id="Aff27"><label/>ACTANE (Anglo/Canadian/Texan/Australian/Norwegian/EU Biomed) Consortium ICPCG Group, Surrey, UK </aff>
        <aff id="Aff28"><label/>Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Surrey, UK </aff>
        <aff id="Aff29"><label/>Strangeways Laboratory, Department of Oncology, Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK </aff>
        <aff id="Aff30"><label/>BC/CA/HI ICPCG Group, Stanford School of Medicine, Stanford, CA USA </aff>
        <aff id="Aff31"><label/>Department of Health Research and Policy, Stanford School of Medicine, Stanford, CA USA </aff>
        <aff id="Aff32"><label/>Stanford Comprehensive Cancer Center, Stanford School of Medicine, Stanford, CA USA </aff>
        <aff id="Aff33"><label/>Department of Urology and Department of Biochemistry and Molecular Biology, University of Southern California, Los Angeles, CA USA </aff>
        <aff id="Aff34"><label/>Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Australia </aff>
        <aff id="Aff35"><label/>Centre for Molecular, Environmental, Genetic and Analytical Epidemiology, University of Melbourne, Melbourne, Australia </aff>
        <aff id="Aff36"><label/>Northwestern University ICPCG Group, Chicago, IL USA </aff>
        <aff id="Aff37"><label/>Northwestern University Feinberg School of Medicine, Chicago, IL USA </aff>
        <aff id="Aff38"><label/>Louisiana State University ICPCG Group, New Orleans, LA USA </aff>
        <aff id="Aff39"><label/>Department of Genetics, Louisiana State University Health Sciences Center, New Orleans, LA USA </aff>
        <aff id="Aff40"><label/>Program in Cancer Genetics, Departments of Oncology and Human Genetics, McGill University, Montreal, QC Canada </aff>
        <aff id="Aff51"><label/>Research Institute of the McGill University Health Centre, Montreal, QC Canada </aff>
        <aff id="Aff41"><label/>The Norwegian Radium Hospital, Oslo, Norway </aff>
        <aff id="Aff42"><label/>African American Hereditary Prostate Cancer ICPCG Group, Detroit, MI USA </aff>
        <aff id="Aff43"><label/>Karmanos Cancer Institute, Wayne State University, Detroit, MI USA </aff>
        <aff id="Aff44"><label/>Inherited Disease Research Branch, National Human Genome Research Institute, NIH, Bethesda, MD USA </aff>
        <aff id="Aff45"><label/>Genetic Basis of Human Disease Research Division, Translational Genomics Research Institute, Phoenix, AZ USA </aff>
        <aff id="Aff46"><label/>National Cancer Institute, NIH, Bethesda, MD USA </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>12</day>
        <month>10</month>
        <year>2012</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>12</day>
        <month>10</month>
        <year>2012</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>1</month>
        <year>2013</year>
      </pub-date>
      <volume>132</volume>
      <issue>1</issue>
      <fpage>5</fpage>
      <lpage>14</lpage>
      <history>
        <date date-type="received">
          <day>13</day>
          <month>7</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>15</day>
          <month>9</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Â© The Author(s) 2012</copyright-statement>
      </permissions>
      <abstract id="Abs1">
        <p>Prostate cancer has a strong familial component but uncovering the molecular basis for inherited susceptibility for this disease has been challenging. Recently, a rare, recurrent mutation (G84E) in <italic>HOXB13</italic> was reported to be associated with prostate cancer risk. Confirmation and characterization of this finding is necessary to potentially translate this information to the clinic. To examine this finding in a large international sample of prostate cancer families, we genotyped this mutation and 14 other SNPs in or flanking <italic>HOXB13</italic> in 2,443 prostate cancer families recruited by the International Consortium for Prostate Cancer Genetics (ICPCG). At least one mutation carrier was found in 112 prostate cancer families (4.6Â %), all of European descent. Within carrier families, the G84E mutation was more common in men with a diagnosis of prostate cancer (194 of 382, 51Â %) than those without (42 of 137, 30Â %), <italic>P</italic>Â =Â 9.9Â ÃÂ 10<sup>â8</sup> [odds ratio 4.42 (95Â % confidence interval 2.56â7.64)]. A family-based association test found G84E to be significantly over-transmitted from parents to affected offspring (<italic>P</italic>Â =Â 6.5Â ÃÂ 10<sup>â6</sup>). Analysis of markers flanking the G84E mutation indicates that it resides in the same haplotype in 95Â % of carriers, consistent with a founder effect. Clinical characteristics of cancers in mutation carriers included features of high-risk disease. These findings demonstrate that the <italic>HOXB13</italic> G84E mutation is present in ~5Â % of prostate cancer families, predominantly of European descent, and confirm its association with prostate cancer risk. While future studies are needed to more fully define the clinical utility of this observation, this allele and others like it could form the basis for early, targeted screening of men at elevated risk for this common, clinically heterogeneous cancer.</p>
        <sec>
          <title>Electronic supplementary material</title>
          <p>The online version of this article (doi:10.1007/s00439-012-1229-4) contains supplementary material, which is available to authorized users.</p>
        </sec>
      </abstract>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>Â© Springer-Verlag Berlin Heidelberg 2013</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p>By sequencing coding regions of more than 200 genes in a previously identified region of linkage at 17q21â22 (Lange et al. <xref ref-type="bibr" rid="CR19">2003</xref>; Gillanders et al. <xref ref-type="bibr" rid="CR10">2004</xref>; Xu et al. <xref ref-type="bibr" rid="CR28">2005</xref>; Lange et al. <xref ref-type="bibr" rid="CR20">2007</xref>; Cropp et al. <xref ref-type="bibr" rid="CR5">2011</xref>) a rare but recurrent mutation (G84E) in <italic>HOXB13</italic> was recently identified in four of 94 probands from prostate cancer families. (Ewing et al. <xref ref-type="bibr" rid="CR9">2012</xref>) The mutation co-segregated with prostate cancer in these four families and was found to be significantly more common among 5,083 unrelated prostate cancer patients (1.4Â %) than control subjects (0.1Â %) of European descent (<italic>p</italic>Â =Â 8.5Â ÃÂ 10<sup>â7</sup>) leading to odds ratio (OR) estimates of tenfold or more. In this initial report, the frequency of the mutation was higher in prostate cancer patients with early-onset disease (age at diagnosis â¤55Â years old, 2.2Â %) or with a positive family history (2.2Â %), and most common in patients with both of these features (3.1Â %). If confirmed, these findings provide support for the concept that rare, moderately penetrant mutations as well as common, low-penetrance prostate cancer risk-associated variants identified from genome-wide association studies (GWAS) (Gudmundsson et al. <xref ref-type="bibr" rid="CR11">2007a</xref>, <xref ref-type="bibr" rid="CR12">b</xref>, <xref ref-type="bibr" rid="CR13">2008</xref>, <xref ref-type="bibr" rid="CR14">2009</xref>; Yeager et al. <xref ref-type="bibr" rid="CR30">2007</xref>, <xref ref-type="bibr" rid="CR31">2009</xref>; Thomas et al. <xref ref-type="bibr" rid="CR26">2008</xref>; Eeles et al. <xref ref-type="bibr" rid="CR7">2008</xref>, <xref ref-type="bibr" rid="CR8">2009</xref>; Sun et al. <xref ref-type="bibr" rid="CR23">2008</xref>; Xu et al. <xref ref-type="bibr" rid="CR29">2010</xref>; Kote-Jarai et al. <xref ref-type="bibr" rid="CR100">2011a</xref>; Takata et al. <xref ref-type="bibr" rid="CR24">2010</xref>; Akamatsu et al. <xref ref-type="bibr" rid="CR2">2012</xref>; Haiman et al. <xref ref-type="bibr" rid="CR15">2011</xref>) both contribute to prostate cancer risk. The identification and characterization of genetic variants reproducibly associated with substantial increases in prostate cancer risk would provide enhanced ability to identify men most likely to benefit from early disease screening.</p>
      <p>Prostate cancer demonstrates wide differences in incidence and mortality across populations within the United States and throughout the world. In an attempt to confirm and expand the observations of Ewing et al. (<xref ref-type="bibr" rid="CR9">2012</xref>), we examined the frequency of <italic>HOXB13</italic> G84E mutations in prostate cancer families across different ancestries and geographic regions. We genotyped this mutation and other known variants in <italic>HOXB13</italic> in 2,443 hereditary prostate cancer families recruited by members of the International Consortium for Prostate Cancer Genetics (ICPCG), a large NCI-funded collaborative resource for studies of genetic susceptibility for hereditary prostate cancer.</p>
    </sec>
    <sec id="Sec2" sec-type="methods">
      <title>Subjects and methods</title>
      <sec id="Sec3">
        <title>Study population</title>
        <p>The ICPCG study cohort has been described in detail previously (Schaid and Chang <xref ref-type="bibr" rid="CR22">2005</xref>; Xu et al. <xref ref-type="bibr" rid="CR28">2005</xref>). Fifteen groups participated in the present study, including those from Europe [Finland (Tampere University), Sweden (Karolinska Institute), UK (Institute of Cancer Research and Royal Marsden NHS Foundation Trust, University of Cambridge, ACTANE), Germany (University of Ulm), and France (CeRePP)], North America (Fred Hutchinson Cancer Research Center, Johns Hopkins Hospital, Louisiana State University, Mayo Clinic, McGill University, Northwestern University, Stanford University, University of Michigan, and University of Utah), and Australia (University of Melbourne) (Supplementary TableÂ 1).</p>
        <p>Each ICPCG group recruited its study population via different methods of pedigree ascertainment and utilized different methods to confirm prostate cancer diagnosis. In this study, men were considered âaffectedâ if their prostate cancer diagnosis was confirmed by either medical records or death certificates. All other men were assigned as âunknown phenotype.â A total of 2,443 families were included in the study, including 6,422 affected men and 1,902 men without a prostate cancer diagnosis (unknown), and 1,803 women whose DNA samples were available (Supplementary TableÂ 1). Research protocols and study documentation were approved by each groupâs Institutional Review Board.</p>
      </sec>
      <sec id="Sec4">
        <title>SNPs selection and genotyping</title>
        <p>Five mutations in the <italic>HOXB13</italic> gene, selected from the original paper of Ewing et al. (<xref ref-type="bibr" rid="CR9">2012</xref>) and the ESP database (Exome Variant Server, NHLBI Exome Sequencing Project, Seattle, WA, USA (URL: <ext-link ext-link-type="uri" xlink:href="http://evs.gs.washington.edu/EVS/">http://evs.gs.washington.edu/EVS/</ext-link>) [1/2012]) were genotyped in the ICPCG dataset, including G84E (c.251GÂ &gt;Â A, rs138213197), T105I (c.314CÂ &gt;Â T, rs140492479), R217C (c.649CÂ &gt;Â T, rs13945791), R229G (c.685CÂ &gt;Â G), and T253P (c.757AÂ &gt;Â C). In addition, ten polymorphic SNPs (rs890435, rs2326017, rs7212669, rs8064938, rs3809773, rs1054072, rs8556, rs3809771, rs4793980, rs3110601) flanking the <italic>HOXB13</italic> gene and spanning 108,191 base pairs (bp) from 46,719,399 to 46,827,590 (Build 37) were genotyped to estimate allele frequencies and haplotypes. The G84E mutation, due to a change in the second position of codon 84 (GGAÂ âÂ GAA), results in a nonconservative substitution in a conserved putative proteinâprotein binding motif of HOXB13 (Ewing et al. <xref ref-type="bibr" rid="CR9">2012</xref>).</p>
        <p>Genotyping was performed using the MassARRAY iPLEX (Sequenom, Inc., San Diego, CA, USA). Duplicates and negative controls were included in each 96-well plate to ensure quality control (QC). Genotyping was performed by technicians blinded to the sample status. The average concordance rate was 99.7Â % for 6,300 genotypes among QC duplicates.</p>
      </sec>
      <sec id="Sec5">
        <title>Statistical methods</title>
        <p>Frequency of the G84E mutation was determined at either family level or individual level. At a family level, the proportion of families with at least one G84E mutation carrier was determined for the entire set as well as for each ICPCG group. The difference in the proportion among different ICPCG groups was tested using Chi-square with a degree of freedom (<italic>df</italic>) of 14. At an individual level, the proportion of G84E mutation carriers was compared among men with a diagnosis of prostate cancer (affecteds) and the remaining men within the families (unknowns). The difference of G84E mutation carrier rate between affected and unknown men was tested based on a marginal model that accounts for relatedness of subjects within families using generalized estimating equations (GEE). An exchangeable working correlation matrix was assumed.</p>
        <p>A family-based association test was performed to test association of the G84E mutation and other SNPs with prostate cancer by assessing over-transmission of alleles from parents to affected offspring using the computer program FBAT (Xu et al. <xref ref-type="bibr" rid="CR27">2002</xref>). Empirical variance test statistics were used to account for the correlation of transmitted alleles among multiple affected individuals in the same family.</p>
        <p>Haplotypes of each individual based on these 15 SNPs were estimated using Genehunter-plus (Kruglyak et al. <xref ref-type="bibr" rid="CR18">1996</xref>) and PLINK (Purcell et al. <xref ref-type="bibr" rid="CR21">2007</xref>). The haplotypes with the highest likelihood were selected. For subjects whose inferred haplotypes were different based on these two methods, manual inspection was performed to resolve the difference, with priority given to haplotypes based on linkage disequilibrium among markers in this study population.</p>
      </sec>
    </sec>
    <sec id="Sec6" sec-type="results">
      <title>Results</title>
      <p>Among five previously observed mutations in <italic>HOXB13</italic> (Ewing et al. <xref ref-type="bibr" rid="CR9">2012</xref>) two were observed in this studyâR217C (rs13945791) and G84E (rs138213197). The rare R217C variant was found one time each in two families of European descent and did not co-segregate with prostate cancer. The G84E mutation was found in 283 subjects from 112 families of European descent, including 194 men with prostate cancer (TableÂ <xref rid="Tab1" ref-type="table">1</xref>). This represented 4.6Â % of all 2,443 prostate cancer families and 4.8Â % of 2,298 prostate cancer families of European descent. The proportion of families with at least one G84E mutation carrier differed significantly across the 15 ICPCG groups (<italic>P</italic>Â =Â 9.4Â ÃÂ 10<sup>â8</sup>). The proportion was highest in families from the Nordic countries of Finland (22.4Â %) and Sweden (8.2Â %) and lower in North America (0â6.1Â %) and Australia (2.6Â %). The G84E mutation was not found in families of any other race or ethnicity, including those of African (<italic>N</italic>Â =Â 58), Ashkenazi Jewish (<italic>N</italic>Â =Â 46), or other descent (<italic>N</italic>Â =Â 28). Obviously, larger numbers of families of these and other races and ethnicities will need to be examined to more fully characterize the population distribution of this mutation.<table-wrap id="Tab1"><label>TableÂ 1</label><caption><p>G84E mutation of <italic>HOXB13</italic> in prostate cancer families of International Consortium for Prostate Cancer Genetics (ICPCG)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3"/><th align="left" rowspan="2" colspan="2">No. of families</th><th align="left" rowspan="2" colspan="2">No. of families with G84E carriers (%)</th><th align="left" colspan="6">Subjects in families with at least one G84E carrier</th></tr><tr><th align="left" colspan="2">Affected</th><th align="left" colspan="2">Unknown (Men)</th><th align="left" colspan="2">Unknown (Women)</th></tr><tr><th align="left">All</th><th align="left">European descent</th><th align="left">All</th><th align="left">European descent</th><th align="left"><italic>N</italic></th><th align="left">No. of G84E carriers (%)</th><th align="left"><italic>N</italic></th><th align="left">No. of G84E carriers (%)</th><th align="left"><italic>N</italic></th><th align="left"><italic>N</italic> of G84E carriers (%)</th></tr></thead><tbody><tr><td align="left" colspan="11">Europe</td></tr><tr><td align="left">Â Finland, University of Tampere</td><td char="." align="char">76</td><td char="." align="char">76</td><td align="left">17 (22.4Â %)</td><td align="left">17 (22.4Â %)</td><td char="." align="char">54</td><td align="left">37 (69Â %)</td><td char="." align="char">69</td><td align="left">22 (31Â %)</td><td char="." align="char">97</td><td align="left">29 (30Â %)</td></tr><tr><td align="left">Â Sweden, Umea University</td><td char="." align="char">110</td><td char="." align="char">110</td><td align="left">9 (8.2Â %)</td><td align="left">9 (8.2Â %)</td><td char="." align="char">17</td><td align="left">13 (76Â %)</td><td char="." align="char">15</td><td align="left">5 (33Â %)</td><td char="." align="char">13</td><td align="left">4 (31Â %)</td></tr><tr><td align="left">Â Germany, University of Ulm</td><td char="." align="char">378</td><td char="." align="char">378</td><td align="left">13 (3.4Â %)</td><td align="left">13 (3.4Â %)</td><td char="." align="char">21</td><td align="left">19 (90Â %)</td><td char="." align="char">1</td><td align="left">0 (0Â %)</td><td char="." align="char">2</td><td align="left">0 (0Â %)</td></tr><tr><td align="left">Â UK, ACTANE</td><td char="." align="char">145</td><td char="." align="char">142</td><td align="left">5 (3.4Â %)</td><td align="left">5 (3.5Â %)</td><td char="." align="char">12</td><td align="left">7 (58Â %)</td><td char="." align="char">1</td><td align="left">0 (0Â %)</td><td char="." align="char">1</td><td align="left">0 (0Â %)</td></tr><tr><td align="left">Â France, CeRePP</td><td char="." align="char">159</td><td char="." align="char">156</td><td align="left">2 (1.3Â %)</td><td align="left">2 (1.3Â %)</td><td char="." align="char">5</td><td align="left">3 (60Â %)</td><td char="." align="char">1</td><td align="left">0 (0Â %)</td><td char="." align="char">0</td><td align="left">0</td></tr><tr><td align="left" colspan="11">North America</td></tr><tr><td align="left">Â BC/CA/HI</td><td char="." align="char">98</td><td char="." align="char">83</td><td align="left">6 (6.1Â %)</td><td align="left">6 (7.2Â %)</td><td char="." align="char">20</td><td align="left">12 (60Â %)</td><td char="." align="char">7</td><td align="left">1 (14Â %)</td><td char="." align="char">7</td><td align="left">1 (14Â %)</td></tr><tr><td align="left">Â Fred Hutchinson Cancer Research Center</td><td char="." align="char">255</td><td char="." align="char">241</td><td align="left">14 (5.5Â %)</td><td align="left">14 (5.8Â %)</td><td char="." align="char">45</td><td align="left">25 (56Â %)</td><td char="." align="char">14</td><td align="left">5 (36Â %)</td><td char="." align="char">16</td><td align="left">2 (13Â %)</td></tr><tr><td align="left">Â Johns Hopkins Hospital<sup>a</sup></td><td char="." align="char">234</td><td char="." align="char">176</td><td align="left">5 (2.1Â %)</td><td align="left">5 (2.8Â %)</td><td char="." align="char">20</td><td align="left">14 (70Â %)</td><td char="." align="char">7</td><td align="left">2 (29Â %)</td><td char="." align="char">10</td><td align="left">4 (40Â %)</td></tr><tr><td align="left">Â MAYO Clinic</td><td char="." align="char">185</td><td char="." align="char">185</td><td align="left">6 (3.2Â %)</td><td align="left">6 (3.2Â %)</td><td char="." align="char">15</td><td align="left">10 (67Â %)</td><td char="." align="char">2</td><td align="left">0 (0Â %)</td><td char="." align="char">0</td><td align="left">0</td></tr><tr><td align="left">Â University of Michigan<sup>a</sup></td><td char="." align="char">317</td><td char="." align="char">282</td><td align="left">11 (3.5Â %)</td><td align="left">11 (3.9Â %)</td><td char="." align="char">36</td><td align="left">26 (72Â %)</td><td char="." align="char">13</td><td align="left">4 (31Â %)</td><td char="." align="char">5</td><td align="left">2 (40Â %)</td></tr><tr><td align="left">Â McGill University</td><td char="." align="char">18</td><td char="." align="char">17</td><td align="left">1 (5.9Â %)</td><td align="left">1 (5.9Â %)</td><td char="." align="char">2</td><td align="left">2 (100Â %)</td><td char="." align="char">0</td><td align="left">0</td><td char="." align="char">0</td><td align="left">0</td></tr><tr><td align="left">Â North Western University</td><td char="." align="char">33</td><td char="." align="char">32</td><td align="left">0 (0Â %)</td><td align="left">0 (0Â %)</td><td char="." align="char">0</td><td align="left">0</td><td char="." align="char">0</td><td align="left">0</td><td char="." align="char">0</td><td align="left">0</td></tr><tr><td align="left">Â University of Utah</td><td char="." align="char">348</td><td char="." align="char">348</td><td align="left">21 (6Â %)</td><td align="left">21 (6Â %)</td><td char="." align="char">132</td><td align="left">23 (17Â %)</td><td char="." align="char">6</td><td align="left">2 (33Â %)</td><td char="." align="char">11</td><td align="left">3 (27Â %)</td></tr><tr><td align="left">Â Louisiana State University</td><td char="." align="char">10</td><td char="." align="char">10</td><td align="left">0 (0Â %)</td><td align="left">0 (0Â %)</td><td char="." align="char">0</td><td align="left">0</td><td char="." align="char">0</td><td align="left">0</td><td char="." align="char">0</td><td align="left">0</td></tr><tr><td align="left" colspan="11">Australia</td></tr><tr><td align="left">Â Australia</td><td char="." align="char">77</td><td char="." align="char">73</td><td align="left">2 (2.6Â %)</td><td align="left">2 (2.7Â %)</td><td char="." align="char">3</td><td align="left">3 (100Â %)</td><td char="." align="char">1</td><td align="left">1 (100Â %)</td><td char="." align="char">3</td><td align="left">2 (67Â %)</td></tr><tr><td align="left">Total</td><td char="." align="char">2,443</td><td char="." align="char">2,309</td><td align="left">112 (4.6Â %)</td><td align="left">112 (4.9Â %)</td><td char="." align="char">382</td><td align="left">194 (51Â %)</td><td char="." align="char">137</td><td align="left">42 (31Â %)</td><td char="." align="char">165</td><td align="left">47 (28Â %)</td></tr><tr><td align="left">Total<sup>a</sup></td><td char="." align="char">1,892</td><td char="." align="char">1,851</td><td align="left">96 (5.0Â %)</td><td align="left">96 (5.2Â %)</td><td char="." align="char">326</td><td align="left">154 (47Â %)</td><td char="." align="char">117</td><td align="left">36 (31Â %)</td><td char="." align="char">150</td><td align="left">41 (27Â %)</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>A subset of families from these centers were included in the original discovery report (Ewing et al. <xref ref-type="bibr" rid="CR9">2012</xref>). These total values reflect the results obtained after omitting all families from these two centers</p></table-wrap-foot></table-wrap></p>
      <p>In the 112 families with at least one G84E mutation carrier, the mutation was found in both affected and unaffected men. However, the carrier rate was significantly higher in affected men (194 of 382, 51Â %) than other men in these families (i.e. men of unknown status [(42 of 137, 31Â %), <italic>p</italic>Â =Â 9.9Â ÃÂ 10<sup>â8</sup>]) (TableÂ <xref rid="Tab1" ref-type="table">1</xref>). Using a statistical test that considered the relatedness of subjects within carrier families, the odds ratio (OR) for prostate cancer was 4.42 [95Â % confidence interval (CI) 2.56â7.64] for the G84E mutation carriers. We repeated our analyses excluding families from the University of Michigan and Johns Hopkins Hospital, some of which were included in the initial report describing <italic>HOXB13</italic> as a prostate cancer susceptibility gene (Ewing et al. <xref ref-type="bibr" rid="CR9">2012</xref>). In particular, the former study included <italic>HOXB13</italic> G84E genotype data from only the youngest prostate cancer case in a subset of University of Michigan and Johns Hopkins Hospital families. The carrier rate in ICPCG families remained significantly higher in affected men (154 of 326, 47Â %) than unknown men [(36 of 117, 31Â %), <italic>P</italic>Â =Â 3.3Â ÃÂ 10<sup>â6</sup>] and the OR for prostate cancer was 4.3 [95Â % confidence interval (CI) 2.32â7.96] for the G84E mutation carriers after excluding all families from these two institutions (TableÂ <xref rid="Tab1" ref-type="table">1</xref>).</p>
      <p>A mixed pattern of co-segregation of the G84E mutation with prostate cancer was found in these 112 families. While complete co-segregation was found in 34 families, incomplete co-segregation was more commonly observed, revealing genetic heterogeneity (affected but not carriers) and incomplete penetrance of the mutation (carriers but unaffected men).</p>
      <p>We also examined transmission of G84E mutation and alleles of other genotyped SNPs at the region in all 2,443 families using a family-based association test (TableÂ <xref rid="Tab2" ref-type="table">2</xref>). The risk allele (A) corresponding to the G84E mutation was observed to be transmitted significantly more often than expected from parents to affected sons (<italic>P</italic>Â =Â 6.5Â ÃÂ 10<sup>â6</sup>). A significant result was also observed when all families from the University of Michigan and Johns Hopkins Hospital were removed from this analysis (<italic>P</italic>Â =Â 1.2Â ÃÂ 10<sup>â4</sup>) (Supplementary TableÂ 2), strongly indicating the G84E mutation is associated with prostate cancer risk.<table-wrap id="Tab2"><label>TableÂ 2</label><caption><p>Family-based association test for SNPs at <italic>HOXB13</italic> region in ICPCG families</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Chr</th><th align="left">Position</th><th align="left">rs#</th><th align="left">Gene</th><th align="left">Mutation</th><th align="left">Rare allele</th><th align="left">Allele frequency</th><th align="left">No. of informative families</th><th align="left">S-E(S)<sup>a</sup></th><th align="left">Var(S)</th><th align="left"><italic>Z</italic></th><th align="left"><italic>P</italic></th></tr></thead><tbody><tr><td align="left">17</td><td align="left">46,719,399</td><td align="left">rs890435</td><td align="left">Intergenic</td><td align="left"/><td align="left">G</td><td align="left">0.41</td><td align="left">509</td><td align="left">â7.38</td><td align="left">243.77</td><td align="left">â0.47</td><td align="left">0.64</td></tr><tr><td align="left">17</td><td align="left">46,720,565</td><td align="left">rs2326017</td><td align="left">Intergenic</td><td align="left"/><td align="left">T</td><td align="left">0.33</td><td align="left">496</td><td align="left">3.10</td><td align="left">248.24</td><td align="left">0.20</td><td align="left">0.84</td></tr><tr><td align="left">17</td><td align="left">46,727,289</td><td align="left">rs7212669</td><td align="left">Intergenic</td><td align="left"/><td align="left">G</td><td align="left">0.10</td><td align="left">244</td><td align="left">â4.89</td><td align="left">107.42</td><td align="left">â0.47</td><td align="left">0.64</td></tr><tr><td align="left">17</td><td align="left">46,780,829</td><td align="left">rs8064938</td><td align="left">Intergenic</td><td align="left"/><td align="left">A</td><td align="left">0.16</td><td align="left">353</td><td align="left">â6.12</td><td align="left">136.42</td><td align="left">â0.52</td><td align="left">0.60</td></tr><tr><td align="left">17</td><td align="left">46,784,039</td><td align="left">rs3809773</td><td align="left">Intergenic</td><td align="left"/><td align="left">A</td><td align="left">0.33</td><td align="left">485</td><td align="left">1.42</td><td align="left">245.54</td><td align="left">0.10</td><td align="left">0.93</td></tr><tr><td align="left">17</td><td align="left">46,799,812</td><td align="left">rs1054072</td><td align="left">PRAC</td><td align="left"/><td align="left">C</td><td align="left">0.47</td><td align="left">518</td><td align="left">â13.41</td><td align="left">268.62</td><td align="left">â0.82</td><td align="left">0.41</td></tr><tr><td align="left">17</td><td align="left">46.804,250</td><td align="left"/><td align="left">HOXB13</td><td align="left">T253P</td><td align="left"/><td align="left">0</td><td align="left">0</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td><td align="left">N/A</td></tr><tr><td align="left">17</td><td align="left">46,804,322</td><td align="left"/><td align="left">HOXB13</td><td align="left">R229G</td><td align="left">G</td><td align="left">0.0001</td><td align="left">1</td><td align="left">â0.40</td><td align="left">0.16</td><td align="left">â1.00</td><td align="left">0.32</td></tr><tr><td align="left">17</td><td align="left">46,804,358</td><td align="left">rs139475791</td><td align="left">HOXB13</td><td align="left">R217C</td><td align="left">A</td><td align="left">0.0001</td><td align="left">2</td><td align="left">â1.60</td><td align="left">1.36</td><td align="left">â1.37</td><td align="left">0.17</td></tr><tr><td align="left">17</td><td align="left">46,805,590</td><td align="left">rs8556</td><td align="left">HOXB13</td><td align="left"/><td align="left">T</td><td align="left">0.15</td><td align="left">342</td><td align="left">â10.77</td><td align="left">145.60</td><td align="left">â0.89</td><td align="left">0.37</td></tr><tr><td align="left">17</td><td align="left">46,805,642</td><td align="left">rs140492479</td><td align="left">HOXB13</td><td align="left">T105I</td><td align="left">A</td><td align="left">0.0001</td><td align="left">2</td><td align="left">1.64</td><td align="left">1.41</td><td align="left">1.38</td><td align="left">0.17</td></tr><tr><td align="left">17</td><td align="left">46,805,705</td><td align="left">rs138213197</td><td align="left">HOXB13</td><td align="left">G84E</td><td align="left">A</td><td align="left">0.02</td><td align="left">38</td><td align="left">17.50</td><td align="left">15.07</td><td align="left">4.51</td><td align="left">6.53Eâ06</td></tr><tr><td align="left">17</td><td align="left">46,807,919</td><td align="left">rs3809771</td><td align="left">5â²</td><td align="left"/><td align="left">G</td><td align="left">0.06</td><td align="left">171</td><td align="left">â8.92</td><td align="left">64.24</td><td align="left">â1.11</td><td align="left">0.27</td></tr><tr><td align="left">17</td><td align="left">46,813,531</td><td align="left">rs4793980</td><td align="left">5â²</td><td align="left"/><td align="left">T</td><td align="left">0.16</td><td align="left">306</td><td align="left">2.22</td><td align="left">116.03</td><td align="left">0.21</td><td align="left">0.84</td></tr><tr><td align="left">17</td><td align="left">46,827,590</td><td align="left">rs3110601</td><td align="left">5â²</td><td align="left">Â </td><td align="left">C</td><td align="left">0.12</td><td align="left">274</td><td align="left">â7.46</td><td align="left">114.18</td><td align="left">â0.70</td><td align="left">0.49</td></tr></tbody></table><table-wrap-foot><p>Based on an FBAT analysis of 2,437 pedigrees (10,217 nuclear families; 40,246 subjects)</p><p><sup>a</sup>S-E(S) is the statistical score for the observed number of rare allele transmissions minus the statistical score for the expected number of transmissions</p></table-wrap-foot></table-wrap></p>
      <p>To assess association in our family set while adjusting for variable pedigree structures, we randomly selected one affected man (proband) in the second generation from each of 2,443 pedigrees and then counted the number of G84E carriers among probands, first-relatives, and second-degree relatives or higher (TableÂ  <xref rid="Tab3" ref-type="table">3</xref>). The G84E mutation carrier rate among probands was 2.8Â %. Among the first-degree relatives, the carrier rate was significantly higher in affected men (75Â %) than in those with an unknown phenotype (48Â %), <italic>P</italic>Â =Â 0.002, ORÂ =Â 4.26 (95Â % CI 1.69â10.75). Among the second-degree relatives or higher, the carrier rate was also significantly higher in affected men (58Â %) than in unknown men (23Â %), <italic>P</italic>Â =Â 0.004, ORÂ =Â 4.81 (95Â % CI 1.64â14.12).<table-wrap id="Tab3"><label>TableÂ 3</label><caption><p>G84E <italic>HOXB13</italic> mutation carriers among randomly selected affected probands and their relatives</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Proband G84E Carrier</th><th align="left" colspan="4">G84E carriers in first-degree relatives</th><th align="left" colspan="4">G84E carriers in second-degree relatives or higher</th></tr><tr><th align="left">Affected</th><th align="left">Unknown</th><th align="left">OR (95Â % CI)</th><th align="left"><italic>P</italic> value</th><th align="left">Affected</th><th align="left">Unknown</th><th align="left">OR (95Â % CI)</th><th align="left"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left">Yes (51)</td><td align="left">56/75 (74.7Â %)</td><td align="left">16/34 (47.6Â %)</td><td align="left">4.26 (1.69â10.75)</td><td align="left">0.002</td><td align="left">11/19 (57.9Â %)</td><td align="left">9/39 (23.1Â %)</td><td align="left">4.81 (1.64â14.12)</td><td align="left">0.004</td></tr><tr><td align="left">No (1,755)</td><td align="left">21/2,502 (0.8Â %)</td><td align="left">3/759 (0.4Â %)</td><td align="left">2.31 (0.82â6.51)</td><td align="left">0.11</td><td align="left">15/973 (1.5Â %)</td><td align="left">6/651 (0.9Â %)</td><td align="left">2.21 (0.39â12.71)</td><td align="left">0.37</td></tr></tbody></table></table-wrap></p>
      <p>The prostate cancer patients who carried the mutation had a wide spectrum of clinical disease, including cancers with high risk of disease progression (TableÂ <xref rid="Tab4" ref-type="table">4</xref>), as indicated by moderate to poor tumor differentiation (tumor grade of Gleason score 7 or higher) in over one-third of the cases with available data, and over one-quarter having non-organ confined disease at diagnosis (tumor stage T3 or higher). The mean age at diagnosis of carriers was 62.8Â years. In comparison, the mean age at diagnosis for the 6,172 prostate cancer patients without the mutation was 64.4Â years (<italic>P</italic>Â =Â 0.04; relatedness of subjects within families was considered). The mean age at last contact of G84E carriers without a prostate cancer diagnosis was 56.3.<table-wrap id="Tab4"><label>TableÂ 4</label><caption><p>Clinicopathologic variables of prostate cancers in <italic>HOXB13</italic> G84E carriers</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">No. of patients</th><th align="left">Â % of patients</th></tr></thead><tbody><tr><td align="left" colspan="3">Tumor grade (Gleason Score)</td></tr><tr><td align="left">Â â¤6</td><td align="left">67</td><td align="left">63.2Â </td></tr><tr><td align="left">Â 7</td><td align="left">32</td><td align="left">30.2Â </td></tr><tr><td align="left">Â 8</td><td align="left">4</td><td align="left">3.8Â </td></tr><tr><td align="left">Â â¥9</td><td align="left">3</td><td align="left">2.8Â </td></tr><tr><td align="left" colspan="3">Tumor stage</td></tr><tr><td align="left">Â T1c or lower</td><td align="left">47</td><td align="left">39.2Â </td></tr><tr><td align="left">Â T2</td><td align="left">41</td><td align="left">34.2Â </td></tr><tr><td align="left">Â T3 or higher</td><td align="left">32</td><td align="left">26.7Â </td></tr><tr><td align="left" colspan="3">Metastasis at diagnosis</td></tr><tr><td align="left">Â Yes</td><td align="left">4</td><td align="left">3.1Â </td></tr><tr><td align="left" colspan="3">Serum PSA level at diagnosis</td></tr><tr><td align="left">Â â¤10</td><td align="left">49</td><td align="left">48.0Â </td></tr><tr><td align="left">Â 11â20</td><td align="left">25</td><td align="left">24.5Â </td></tr><tr><td align="left">Â â¥20</td><td align="left">28</td><td align="left">27.5Â </td></tr><tr><td align="left" colspan="3">Age at diagnosis</td></tr><tr><td align="left">Â â¤55</td><td align="left">24</td><td align="left">18.6Â </td></tr><tr><td align="left">Â 56â80</td><td align="left">105</td><td align="left">81.4Â </td></tr><tr><td align="left">Â â¥80</td><td align="left">0</td><td align="left">0.0Â </td></tr><tr><td align="left" colspan="3">Death from prostate cancer</td></tr><tr><td align="left">Â Yes</td><td align="left">9</td><td align="left">7.0Â </td></tr></tbody></table></table-wrap></p>
      <p>Finally, to assess a potential founder effect for the G84E mutation, we estimated haplotypes based on the 15 genotyped SNPs in this region. The mutation (allele A) of G84E was predicted to be on eight different haplotypes. However, 95Â % (269 out of 283) of the occurrences were predicted to be on a single rare haplotype (frequency of 2Â %). Among the 269 G84E mutation carriers predicted to carry the common haplotype, 83 were from Finland while the remaining were from 12 other ICPCG groups. One individual from Finland was homozygous for all 15 markers, allowing unambiguous assignment of the haplotype. This individual was diagnosed with moderately differentiated (Gleason 7), clinically localized prostate cancer at age 60.</p>
      <p>We note that the genotype data for all 269 G84E mutation carriers were consistent with a single shared haplotype spanning the 15 genotyped SNPs (i.e. there were no SNPs that had homozygous genotypes for opposite alleles among the 269 carriers) and it is possible that with additional genotype data the most likely haplotype configuration for G84E carriers would be a single founder haplotype.</p>
    </sec>
    <sec id="Sec7" sec-type="discussion">
      <title>Discussion</title>
      <p>By evaluating germline mutations of the <italic>HOXB13</italic> gene in 2,433 prostate cancer families from the ICPCG, this study confirmed the observation that the G84E mutation is significantly associated with prostate cancer in subjects of European descent with family history of the disease. The results remained significant when families used in the original report were not included in the analysis, providing independent confirmation of the original finding. Although there is a large degree of variability in the number of individuals sampled per pedigree in the ICPCG, approximately 5Â % of prostate cancer families had at least one member with the G84E mutation. These results are consistent with the hypothesis that <italic>HOXB13</italic> G84E is a prostate cancer susceptibility allele that significantly increases the risk of prostate cancer.</p>
      <p>The search for hereditary prostate cancer genes has been challenging due to a number of factors including the late-onset nature of the disease and the high background rate of sporadic disease in the general population. Although rare variants of other genes such as <italic>RNASEL</italic> (Carpten et al. <xref ref-type="bibr" rid="CR4">2002</xref>), <italic>MSR1</italic> (Xu et al. <xref ref-type="bibr" rid="CR27">2002</xref>), and <italic>ELAC2</italic> (Tavtigian et al. <xref ref-type="bibr" rid="CR25">2001</xref>) have been previously identified in prostate cancer families and proposed as prostate cancer susceptibility alleles, follow-up studies have not supported their candidacy. On the other hand, mutations in <italic>BRCA2</italic> have been reproducibly associated with prostate cancer risk (Edwards et al. <xref ref-type="bibr" rid="CR6">2003</xref>), but their frequency is low in prostate cancer families (Agalliu et al. <xref ref-type="bibr" rid="CR1">2007</xref>; Kote-Jarai et al. <xref ref-type="bibr" rid="CR17">2011b</xref>).</p>
      <p>More recently, GWAS studies have led to the identification of over 40 prostate cancer risk-associated SNPs that have been replicated in multiple study populations. These variants are common in the general population (5Â % or higher), confer low risk with ORs, typically in the range of 1.1â1.4 (Gudmundsson et al. <xref ref-type="bibr" rid="CR11">2007a</xref>, <xref ref-type="bibr" rid="CR12">b</xref>, <xref ref-type="bibr" rid="CR13">2008</xref>, <xref ref-type="bibr" rid="CR14">2009</xref>; Yeager et al. <xref ref-type="bibr" rid="CR30">2007</xref>, <xref ref-type="bibr" rid="CR31">2009</xref>; Thomas et al. <xref ref-type="bibr" rid="CR26">2008</xref>; Eeles et al. <xref ref-type="bibr" rid="CR7">2008</xref>, <xref ref-type="bibr" rid="CR8">2009</xref>; Sun et al. <xref ref-type="bibr" rid="CR23">2008</xref>; Xu et al. <xref ref-type="bibr" rid="CR29">2010</xref>; Kote-Jarai et al. <xref ref-type="bibr" rid="CR100">2011a</xref>; Takata et al. <xref ref-type="bibr" rid="CR24">2010</xref>; Akamatsu et al. <xref ref-type="bibr" rid="CR2">2012</xref>; Haiman et al. <xref ref-type="bibr" rid="CR15">2011</xref>), and have been estimated to account for ~25Â % of the risk associated with a positive family history (Kote-Jarai et al. <xref ref-type="bibr" rid="CR100">2011a</xref>). Although more common prostate cancer risk-associated variants are likely to be identified in the future, rare variants with larger effects have been proposed as an alternative mechanism to account for âmissing inheritanceâ (Iyengar and Elston <xref ref-type="bibr" rid="CR16">2007</xref>; Bodmer and Bonilla <xref ref-type="bibr" rid="CR3">2008</xref>). In this respect, the establishment of a rare and moderate- to high-penetrance mutation in <italic>HOXB13</italic> as a prostate cancer susceptibility allele provides empirical evidence for this alternative hypothesis. Indeed, like colorectal and breast cancer, at least some significant fraction of prostate cancer risk is conferred by this class of coding sequence variants.</p>
      <p>The estimated frequency of the <italic>HOXB13</italic> G84E mutation in prostate cancer families is influenced by the number of individuals in any given family as well as family structure. For example, some extended families, particularly in the Utah collection, have more than 100 subjects and have multiple affected generations. Similarly, estimated ORs for G84E in relation to prostate cancer risk are impacted by the mixed degrees of relatedness among relatives, as the covariance matrices used in the GEE models do not explicitly account for family structure. The analysis presented in TableÂ <xref rid="Tab3" ref-type="table">3</xref> was designed to provide better odds ratio estimates for first- and second-degree relatives of G84E carriers. Of interest, the carrier rate was lower among second-degree affected relatives (58Â %) compared with first-degree affected relatives (75Â %), suggesting the presence of genetic heterogeneity across families. The OR estimates from our analyses should be interpreted only in the context of the current study. We note that the odds ratios are calculated based on many âcontrolsâ that have limited phenotype information; most have not been screened for disease or screening results are missing. Further, familial controls not currently affected by prostate cancer are more likely to develop disease in the future compared with randomly selected men from the general population given the strong history of disease in these families. Finally, our familial cases are more likely to carry moderate to high penetrance risk alleles compared with typical unselected prostate cancer cases. Large population-based studies that include screened men will be necessary to obtain more accurate measures of G84E mutation frequency and penetrance. As we observed, the frequency of G84E mutations are likely population specific.</p>
      <p>Our results implicate a geographical frequency gradient of the G84E mutation across the European continent, with the mutation being more common in Nordic countries, notably Finland. This finding highlights the strength of the current study as family-based association methods provide the strongest protection against type I error due to population stratification. It remains to be seen how various analytic methods (e.g. those based on principal components that capture the major sources of genetic variation between subjects across common genetic variants) will protect against population stratification when analyzing uncommon genetic variants that disproportionately occur in specific European-derived populations in caseâcontrol settings.</p>
      <p>In summary, analysis of the large ICPCG family collection establishes the <italic>HOXB13</italic> G84E allele as a reproducible risk factor for prostate cancer. Our identification of a common haplotype among the majority of <italic>HOXB13</italic> G84E carriers indicates that there is a founder effect with a higher frequency of the mutant allele in Nordic populations. Additional studies using population-based caseâcontrol and/or familial samples will be useful to define the penetrance of this mutation, which will have important clinical implications for families that carry the G84E mutation.</p>
    </sec>
    <sec sec-type="supplementary-material" id="AppESM1">
      <title>Electronic supplementary material</title>
      <sec id="SecESM1">
        <p>
          <supplementary-material content-type="local-data" id="MOESM1">
            <media xlink:href="439_2012_1229_MOESM1_ESM.docx" mimetype="application" mime-subtype="msword">
              <caption>
                <p>Supplementary material 1 (DOCX 346Â kb)</p>
              </caption>
            </media>
          </supplementary-material>
        </p>
        <p>
          <supplementary-material content-type="local-data" id="MOESM2">
            <media xlink:href="439_2012_1229_MOESM2_ESM.docx" mimetype="application" mime-subtype="msword">
              <caption>
                <p>Supplementary material 2 (DOCX 614Â kb)</p>
              </caption>
            </media>
          </supplementary-material>
        </p>
      </sec>
    </sec>
  </body>
  <back>
    <ack>
      <p>We would like to express our gratitude to the many families who participated in the studies involved in the International Consortium for Prostate Cancer Genetics (ICPCG). The ICPCG is funded by a grant from the National Institutes of Health U01 CA89600 (to W.B.I.). Additional support to members within the ICPCG is as follows: University of Michigan Group acknowledges NIH grants R01 CA79596, R01 CA079596-10-S1 (ARRA), R01 CA136621, and P50 CA69568. University of Utah Group: The authors thank the support from the University of Utah Huntsman Cancer Institute (to Lisa A. Cannon-Albright). FHCRC/NHGRI Group: Partial support was provided by the Fred Hutchinson Cancer Research Center (to Janet L. Stanford) and National Human Genome Research Institute (to Elaine A. Ostrander). ACTANE Group: We acknowledge support from CR-UK grant C5047/A7357 and the NIHR to the Biomedical Research Centre at The Institute of Cancer Research and Royal Marsden NHS Foundation Trust and Prostate Action (to Ros Eeles), and Cancer Research UK (to Doug Easton). This work was also supported by the European Commissionâs Seventh Framework Programme grant agreement nÂ° 223175 (HEALTH-F2-2009-223175), University of UmeÃ¥ Group: Partial support was provided by Swedish Cancer Society and a Spear grant from the UmeÃ¥ University Hospital, UmeÃ¥, Sweden (to Henrik GrÃ¶nberg). University of Tampere Group: Partial support was provided from The Competitive Research Funding of the Pirkanmaa Hospital District (9M094), Finnish Cancer Organisations, Sigrid Juselius Foundation and Academy of Finland (116437 and 251074) (to Johanna Schleutker). Australian Group: Recruitment was funded by Cancer Council Victoria, Tattersalls and The Whitten Foundation; JLH is an Australia Fellow of the National Health and Medical Research Council. Northwestern University Group: Partial support was provided from Robert H Lurie Comprehensive Cancer Center and the Urological Research Foundation (to William J. Catalona). LSUHSC-NO Group: Louisiana Board of Regents, Centers for Disease Control and Prevention. Data Coordinating Center: Partial support was provided by NCI CA119069 and CA129684 (to Jianfeng Xu). We also thank other investigators who contributed to this work: ACTANE Group: Daniel Leongamornlert, Ed Saunders, Malgorzata Tymrakiewicz, Lynne OâBrien, Emma Sawyer, Rosemary Wilkinson, and Stephen Edwards from The Institute of Cancer Research, Sutton, Surrey; Jacques Simard, from the Human Molecular Endocrinology Research Center, CHUL Research Center, Laval University, Quebec City, Canada; Timothy Bishop from Cancer Research UK, Genetic Epidemiology Laboratory, St Jamesâ University Hospital, Leeds, UK; Michael Badzioch; Tokhir Dadaev, Lesley McGuffog, Koveela Govindasami, and Michelle Guy from the UKGPCS Team. University of Ulm Group: Antje Rinckleb and Mark Schrader from Department of Urology, University of Ulm, Germany; Josef Hoegel and Christian Kubisch from Institute of Human Genetics, University of Ulm, Germany; and Kathleen Herkommer from Department of Urology, Technical University of Munich, Germany. Fred Hutchinson Cancer Research Center Group: Laura McIntosh. We thank Liesel FitzGerald for helpful comments and review. William Foulkes thanks Celia Greenwood for advice.</p>
      <sec id="d29e3080">
        <title>Open Access</title>
        <p>This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</p>
      </sec>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Agalliu</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Karlins</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kwon</surname>
              <given-names>EM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer</article-title>
          <source>Br J Cancer</source>
          <year>2007</year>
          <volume>97</volume>
          <fpage>826</fpage>
          <lpage>831</lpage>
          <pub-id pub-id-type="doi">10.1038/sj.bjc.6603929</pub-id>
          <pub-id pub-id-type="pmid">17700570</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR2">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Akamatsu</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Takata</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Haiman</surname>
              <given-names>CA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Common variants at 11q12, 10q26 and 3p11.2 are associated with prostate cancer susceptibility in Japanese</article-title>
          <source>Nat Genet</source>
          <year>2012</year>
          <volume>44</volume>
          <issue>426â9</issue>
          <fpage>S1</fpage>
        </mixed-citation>
      </ref>
      <ref id="CR3">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bodmer</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Bonilla</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Common and rare variants in multifactorial susceptibility to common diseases</article-title>
          <source>Nat Genet</source>
          <year>2008</year>
          <volume>40</volume>
          <issue>6</issue>
          <fpage>695</fpage>
          <lpage>701</lpage>
          <pub-id pub-id-type="doi">10.1038/ng.f.136</pub-id>
          <pub-id pub-id-type="pmid">18509313</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR4">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carpten</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Nupponen</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Isaacs</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Germline mutations in the ribonuclease L gene in families showing linkage with HPC1</article-title>
          <source>Nat Genet</source>
          <year>2002</year>
          <volume>30</volume>
          <fpage>181</fpage>
          <lpage>184</lpage>
          <pub-id pub-id-type="doi">10.1038/ng823</pub-id>
          <pub-id pub-id-type="pmid">11799394</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR5">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cropp</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Simpson</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Wahlfors</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ha</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>George</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Harper</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Ponciano-Jackson</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Green</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Tammela</surname>
              <given-names>TL</given-names>
            </name>
            <name>
              <surname>Bailey-Wilson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Schleutker</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Genome-wide linkage scan for prostate cancer susceptibility in Finland: evidence for a novel locus on 2q37.3 and confirmation of signal on 17q21âq22</article-title>
          <source>Int J Cancer</source>
          <year>2011</year>
          <volume>129</volume>
          <fpage>2400</fpage>
          <lpage>2407</lpage>
          <pub-id pub-id-type="doi">10.1002/ijc.25906</pub-id>
          <pub-id pub-id-type="pmid">21207418</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR6">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Edwards</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Kote-Jarai</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Meitz</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene</article-title>
          <source>Am J Hum Genet</source>
          <year>2003</year>
          <volume>72</volume>
          <fpage>1</fpage>
          <lpage>12</lpage>
          <pub-id pub-id-type="doi">10.1086/345310</pub-id>
          <pub-id pub-id-type="pmid">12474142</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR7">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eeles</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Kote-Jarai</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Giles</surname>
              <given-names>GG</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Multiple newly identified loci associated with prostate cancer susceptibility</article-title>
          <source>Nat Genet</source>
          <year>2008</year>
          <volume>40</volume>
          <fpage>316</fpage>
          <lpage>321</lpage>
          <pub-id pub-id-type="doi">10.1038/ng.90</pub-id>
          <pub-id pub-id-type="pmid">18264097</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR8">
        <mixed-citation publication-type="other">Eeles RA, Kote-Jarai Z, Al Olama AA et al (2009) Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet 41:1116â1121</mixed-citation>
      </ref>
      <ref id="CR9">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ewing</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Ray</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Lange</surname>
              <given-names>EM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Germline mutations in HOXB13 and prostate-cancer risk</article-title>
          <source>N Engl J Med</source>
          <year>2012</year>
          <volume>366</volume>
          <fpage>141</fpage>
          <lpage>149</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1110000</pub-id>
          <pub-id pub-id-type="pmid">22236224</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR10">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gillanders</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>BL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Combined genome-wide scan for prostate cancer susceptibility genes</article-title>
          <source>J Natl Cancer Inst</source>
          <year>2004</year>
          <volume>96</volume>
          <fpage>1240</fpage>
          <lpage>1247</lpage>
          <pub-id pub-id-type="doi">10.1093/jnci/djh228</pub-id>
          <pub-id pub-id-type="pmid">15316059</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR11">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gudmundsson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sulem</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Manolescu</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24</article-title>
          <source>Nat Genet</source>
          <year>2007</year>
          <volume>39</volume>
          <fpage>631</fpage>
          <lpage>637</lpage>
          <pub-id pub-id-type="doi">10.1038/ng1999</pub-id>
          <pub-id pub-id-type="pmid">17401366</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR12">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gudmundsson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sulem</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Steinthorsdottir</surname>
              <given-names>V</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes</article-title>
          <source>Nat Genet</source>
          <year>2007</year>
          <volume>39</volume>
          <fpage>977</fpage>
          <lpage>983</lpage>
          <pub-id pub-id-type="doi">10.1038/ng2062</pub-id>
          <pub-id pub-id-type="pmid">17603485</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR13">
        <mixed-citation publication-type="other">Gudmundsson J, Sulem P, Rafnar T et al (2008) Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet 40:281â283</mixed-citation>
      </ref>
      <ref id="CR14">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gudmundsson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sulem</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gudbjartsson</surname>
              <given-names>DF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility</article-title>
          <source>Nat Genet</source>
          <year>2009</year>
          <volume>41</volume>
          <fpage>1122</fpage>
          <lpage>1126</lpage>
          <pub-id pub-id-type="doi">10.1038/ng.448</pub-id>
          <pub-id pub-id-type="pmid">19767754</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR15">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haiman</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>GK</given-names>
            </name>
            <name>
              <surname>Blot</surname>
              <given-names>WJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21</article-title>
          <source>Nat Genet</source>
          <year>2011</year>
          <volume>43</volume>
          <fpage>570</fpage>
          <lpage>573</lpage>
          <pub-id pub-id-type="doi">10.1038/ng.839</pub-id>
          <pub-id pub-id-type="pmid">21602798</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR16">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Iyengar</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Elston</surname>
              <given-names>RC</given-names>
            </name>
          </person-group>
          <article-title>The genetic basis of complex traits: rare variants or âcommon gene, common diseaseâ</article-title>
          <source>Methods Mol Biol</source>
          <year>2007</year>
          <volume>376</volume>
          <fpage>71</fpage>
          <lpage>84</lpage>
          <pub-id pub-id-type="doi">10.1007/978-1-59745-389-9_6</pub-id>
          <pub-id pub-id-type="pmid">17984539</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR100">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kote-Jarai</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Olama</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Giles</surname>
              <given-names>GG</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study</article-title>
          <source>Nat Genet</source>
          <year>2011</year>
          <volume>43</volume>
          <fpage>785</fpage>
          <lpage>791</lpage>
          <pub-id pub-id-type="doi">10.1038/ng.882</pub-id>
          <pub-id pub-id-type="pmid">21743467</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR17">
        <mixed-citation publication-type="other">Kote-Jarai Z, Leongamornlert D, Saunders E, Tymrakiewicz M, Castro E, Mahmud N, Guy M, Edwards S, OâBrien L, Sawyer E, Hall A, Wilkinson R, Dadaev T, Goh C, Easton D, UKGPCS Collaborators, Goldgar D, Eeles R (2011b) BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer 105(8):1230â1234. doi:10.1038/bjc.2011.383</mixed-citation>
      </ref>
      <ref id="CR18">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kruglyak</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Daly</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Reeve-Daly</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Lander</surname>
              <given-names>ES</given-names>
            </name>
          </person-group>
          <article-title>Parametric and nonparametric linkage analysis: a unified multipoint approach</article-title>
          <source>Am J Hum Genet</source>
          <year>1996</year>
          <volume>58</volume>
          <fpage>1347</fpage>
          <lpage>1363</lpage>
          <pub-id pub-id-type="pmid">8651312</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR19">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lange</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Gillanders</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>CC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Genome-wide scan for prostate cancer susceptibility genes using families from the University of Michigan prostate cancer genetics project finds evidence for linkage on chromosome 17 near BRCA1</article-title>
          <source>Prostate</source>
          <year>2003</year>
          <volume>57</volume>
          <fpage>326</fpage>
          <lpage>334</lpage>
          <pub-id pub-id-type="doi">10.1002/pros.10307</pub-id>
          <pub-id pub-id-type="pmid">14601029</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR20">
        <mixed-citation publication-type="other">Lange EM, Robbins CM, Gillanders EM et al (2007) Fine-mapping the putative chromosome 17q21â22 prostate cancer susceptibility gene to a 10Â cM region based on linkage analysis. Hum Genet 121:49â55</mixed-citation>
      </ref>
      <ref id="CR21">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Purcell</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Neale</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Todd-Brown</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>PLINK: a tool set for whole-genome association and population-based linkage analyses</article-title>
          <source>Am J Hum Genet</source>
          <year>2007</year>
          <volume>81</volume>
          <fpage>559</fpage>
          <lpage>575</lpage>
          <pub-id pub-id-type="doi">10.1086/519795</pub-id>
          <pub-id pub-id-type="pmid">17701901</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR22">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schaid</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>BL</given-names>
            </name>
          </person-group>
          <article-title>Description of the international consortium for prostate cancer genetics, and failure to replicate linkage of hereditary prostate cancer to 20q13</article-title>
          <source>Prostate</source>
          <year>2005</year>
          <volume>63</volume>
          <fpage>276</fpage>
          <lpage>290</lpage>
          <pub-id pub-id-type="doi">10.1002/pros.20198</pub-id>
          <pub-id pub-id-type="pmid">15599943</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR23">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sun</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Wiklund</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12</article-title>
          <source>Nat Genet</source>
          <year>2008</year>
          <volume>40</volume>
          <fpage>1153</fpage>
          <lpage>1155</lpage>
          <pub-id pub-id-type="doi">10.1038/ng.214</pub-id>
          <pub-id pub-id-type="pmid">18758462</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR24">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Takata</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Akamatsu</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kubo</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population</article-title>
          <source>Nat Genet</source>
          <year>2010</year>
          <volume>42</volume>
          <fpage>751</fpage>
          <lpage>754</lpage>
          <pub-id pub-id-type="doi">10.1038/ng.635</pub-id>
          <pub-id pub-id-type="pmid">20676098</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR25">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tavtigian</surname>
              <given-names>SV</given-names>
            </name>
            <name>
              <surname>Simard</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Teng</surname>
              <given-names>DH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A candidate prostate cancer susceptibility gene at chromosome 17p</article-title>
          <source>Nat Genet</source>
          <year>2001</year>
          <volume>27</volume>
          <fpage>172</fpage>
          <lpage>180</lpage>
          <pub-id pub-id-type="doi">10.1038/84808</pub-id>
          <pub-id pub-id-type="pmid">11175785</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR26">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thomas</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Jacobs</surname>
              <given-names>KB</given-names>
            </name>
            <name>
              <surname>Yeager</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Multiple loci identified in a genome-wide association study of prostate cancer</article-title>
          <source>Nat Genet</source>
          <year>2008</year>
          <volume>40</volume>
          <fpage>310</fpage>
          <lpage>315</lpage>
          <pub-id pub-id-type="doi">10.1038/ng.91</pub-id>
          <pub-id pub-id-type="pmid">18264096</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR27">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Komiya</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk</article-title>
          <source>Nat Genet</source>
          <year>2002</year>
          <volume>32</volume>
          <fpage>321</fpage>
          <lpage>325</lpage>
          <pub-id pub-id-type="doi">10.1038/ng994</pub-id>
          <pub-id pub-id-type="pmid">12244320</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR28">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Dimitrov</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>BL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics</article-title>
          <source>Am J Hum Genet</source>
          <year>2005</year>
          <volume>77</volume>
          <fpage>219</fpage>
          <lpage>229</lpage>
          <pub-id pub-id-type="doi">10.1086/432377</pub-id>
          <pub-id pub-id-type="pmid">15988677</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR29">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Isaacs</surname>
              <given-names>SD</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Inherited genetic variant predisposes to aggressive but not indolent prostate cancer</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>2010</year>
          <volume>107</volume>
          <fpage>2136</fpage>
          <lpage>2140</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.0914061107</pub-id>
          <pub-id pub-id-type="pmid">20080650</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR30">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yeager</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Orr</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Hayes</surname>
              <given-names>RB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Genome-wide association study of prostate cancer identifies a second risk locus at 8q24</article-title>
          <source>Nat Genet</source>
          <year>2007</year>
          <volume>39</volume>
          <fpage>645</fpage>
          <lpage>649</lpage>
          <pub-id pub-id-type="doi">10.1038/ng2022</pub-id>
          <pub-id pub-id-type="pmid">17401363</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR31">
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yeager</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Chatterjee</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ciampa</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Identification of a new prostate cancer susceptibility locus on chromosome 8q24</article-title>
          <source>Nat Genet</source>
          <year>2009</year>
          <volume>41</volume>
          <fpage>1055</fpage>
          <lpage>1057</lpage>
          <pub-id pub-id-type="doi">10.1038/ng.444</pub-id>
          <pub-id pub-id-type="pmid">19767755</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
    <fn-group>
      <fn>
        <p>K. A. Cooney and W. B. Isaacs are Co-Senior Authors.</p>
      </fn>
      <fn>
        <p>
          <bold>NOTE Added in Proof:</bold>
        </p>
        <p>While this manuscript was under review, several papers (1-4) demonstrating the significant association of HOXB13 G84E with prostate cancer risk, in familial as well as population-studies, were published, further establishing this mutation as a prostate cancer susceptibility allele.</p>
        <p>1. Akbari MR, Trachtenberg J, Lee J, Tam S, Bristow R, Loblaw A, Narod SA, Nam RK. Association between Germline HOXB13 G84E Mutation and Risk of Prostate Cancer. J Natl Cancer Inst. 2012 Jul 9. [Epub ahead of print]. PMID: 22781434 [PubMedâas supplied by publisher]</p>
        <p>2. Breyer JP, Avritt TG, McReynolds KM, Dupont WD, Smith JR. Confirmation of the HOXB13 G84E Germline Mutation in Familial Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1348â53. Epub 2012 Jun 19. PMID: 22714738 [PubMedâin process]</p>
        <p>3. Karlsson R, Aly M, Clements M, Zheng L, Adolfsson J, Xu J, GrÃ¶nberg H, Wiklund F. A Population-based Assessment of Germline HOXB13 G84E Mutation and Prostate Cancer Risk. Eur Urol. 2012 Jul 20. [Epub ahead of print]. PMID: 22841674 [PubMedâas supplied by publisher]</p>
        <p>4. Stott-Miller M, Karyadi DM, King T, Kwon EM, Kolb S, Stanford JL, Ostrander EA (2012) HOXB13 mutations in a population-based, case control study of prostate cancer. The Prostate (in press)</p>
      </fn>
    </fn-group>
  </back>
</article>

</metadata></record></GetRecord></OAI-PMH>